Suvi Lappalainen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2095331/publications.pdf

Version: 2024-02-01

32 papers	909 citations	471509 17 h-index	454955 30 g-index
32 all docs	32 docs citations	32 times ranked	868 citing authors

#	Article	IF	Citations
1	Antigenicity and immunogenicity of HA2 and M2e influenza virus antigens conjugated to norovirus-like, VP1 capsid-based particles by the SpyTag/SpyCatcher technology. Virology, 2022, 566, 89-97.	2.4	8
2	Expression of influenza A virus-derived peptides on a rotavirus VP6-based delivery platform. Archives of Virology, 2021, 166, 213-217.	2.1	4
3	Modular vaccine platform based on the norovirus-like particle. Journal of Nanobiotechnology, 2021, 19, 25.	9.1	15
4	Fusion Protein of Rotavirus VP6 and SARS-CoV-2 Receptor Binding Domain Induces T Cell Responses. Vaccines, 2021, 9, 733.	4.4	4
5	Rotavirus Inner Capsid VP6 Acts as an Adjuvant in Formulations with Particulate Antigens Only. Vaccines, 2020, 8, 365.	4.4	7
6	Internalization and antigen presentation by mouse dendritic cells of rotavirus VP6 preparations differing in nanostructure. Molecular Immunology, 2020, 123, 26-31.	2.2	6
7	Rotavirus VP6 Adjuvant Effect on Norovirus GII.4 Virus-Like Particle Uptake and Presentation by Bone Marrow-Derived Dendritic Cells In Vitro and In Vivo. Journal of Immunology Research, 2020, 2020, 1-14.	2.2	10
8	Formalin treatment increases the stability and immunogenicity of coxsackievirus B1 VLP vaccine. Antiviral Research, 2019, 171, 104595.	4.1	15
9	A comparative study of the effect of UV and formalin inactivation on the stability and immunogenicity of a Coxsackievirus B1 vaccine. Vaccine, 2019, 37, 5962-5971.	3.8	19
10	Combination of three virus-derived nanoparticles as a vaccine against enteric pathogens; enterovirus, norovirus and rotavirus. Vaccine, 2019, 37, 7509-7518.	3.8	19
11	Functionality and avidity of norovirus-specific antibodies and T cells induced by GII.4 virus-like particles alone or co-administered with different genotypes. Vaccine, 2018, 36, 484-490.	3.8	6
12	Intradermal and intranasal immunizations with oligomeric middle layer rotavirus VP6 induce Th1, Th2 and Th17â€T cell subsets and CD4 + T lymphocytes with cytotoxic potential. Antiviral Research, 2018, 157, 1-8.	4.1	7
13	Parenterally Administered Norovirus GII.4 Virus-Like Particle Vaccine Formulated with Aluminum Hydroxide or Monophosphoryl Lipid A Adjuvants Induces Systemic but Not Mucosal Immune Responses in Mice. Journal of Immunology Research, 2018, 2018, 1-8.	2.2	8
14	Live baculovirus acts as a strong B and T cell adjuvant for monomeric and oligomeric protein antigens. Virology, 2017, 511, 114-122.	2.4	18
15	Rotavirus vaccination and infection induce VP6â€specific IgA responses. Journal of Medical Virology, 2017, 89, 239-245.	5.0	8
16	Rotavirus Recombinant VP6 Nanotubes Act as an Immunomodulator and Delivery Vehicle for Norovirus Virus-Like Particles. Journal of Immunology Research, 2016, 2016, 1-13.	2.2	29
17	Simple and efficient ultrafiltration method for purification of rotavirus VP6 oligomeric proteins. Archives of Virology, 2016, 161, 3219-3223.	2.1	12
18	Rotavirus capsid VP6 protein acts as an adjuvant in vivo for norovirus virus-like particles in a combination vaccine. Human Vaccines and Immunotherapeutics, 2016, 12, 740-748.	3.3	30

#	Article	IF	Citations
19	Protection against live rotavirus challenge in mice induced by parenteral and mucosal delivery of VP6 subunit rotavirus vaccine. Archives of Virology, 2015, 160, 2075-2078.	2.1	43
20	Commonly circulating human coronaviruses do not have a significant role in the etiology of gastrointestinal infections in hospitalized children. Journal of Clinical Virology, 2015, 62, 114-117.	3.1	22
21	Genotype Considerations for Virus-Like Particle-Based Bivalent Norovirus Vaccine Composition. Vaccine Journal, 2015, 22, 656-663.	3.1	31
22	Immune responses elicited against rotavirus middle layer protein VP6 inhibit viral replication in vitro and in vivo. Human Vaccines and Immunotherapeutics, 2014, 10, 2039-2047.	3.3	43
23	Human bocaviruses are commonly found in stools of hospitalized children without causal association to acute gastroenteritis. European Journal of Pediatrics, 2014, 173, 1051-1057.	2.7	40
24	Trivalent Combination Vaccine Induces Broad Heterologous Immune Responses to Norovirus and Rotavirus in Mice. PLoS ONE, 2013, 8, e70409.	2.5	88
25	Comparative immunogenicity in mice of rotavirus VP6 tubular structures and virus-like particles. Human Vaccines and Immunotherapeutics, 2013, 9, 1991-2001.	3.3	31
26	A comparison of immunogenicity of norovirus GIIâ€4 virusâ€like particles and Pâ€particles. Immunology, 2012, 135, 89-99.	4.4	83
27	Simultaneous presence of human herpesvirus 6 and adenovirus infections in intestinal intussusception of young children. Acta Paediatrica, International Journal of Paediatrics, 2012, 101, 663-670.	1.5	27
28	Human bocavirus types 1, 2 and 3 in acute gastroenteritis of childhood. Acta Paediatrica, International Journal of Paediatrics, 2012, 101, e405-10.	1.5	31
29	Rotavirus gastroenteritis in Finnish children in 2006â€“2008, at the introduction of rotavirus vaccination. Scandinavian Journal of Infectious Diseases, 2011, 43, 58-63.	1.5	30
30	Norovirus VLPs and rotavirus VP6 protein as combined vaccine for childhood gastroenteritis. Vaccine, 2011, 29, 8126-8133.	3.8	123
31	Noroviruses in children seen in a hospital for acute gastroenteritis in Finland. European Journal of Pediatrics, 2011, 170, 1413-1418.	2.7	28
32	Detection of human coronaviruses in children with acute gastroenteritis. Journal of Clinical Virology, 2010, 48, 27-30.	3.1	64